Search

Ayodele Olaolu Oladejo,1,2 Yajuan Li,1 Bereket Habte Imam,1,3 Xiaoyu Ma,1 Wenxiang Shen,1 Xiaohu Wu,1 Wei Jiang,1 Jie Yang,1 Yanan Lv,1 Xuezhi Ding,1 Shengyi Wang,1 Zuoting Yan1 1Key Laboratory of Veterinary Pharmaceutical Development of Ministry of Agriculture, Lanzhou Institute of Husbandry and Pharmaceutical Sciences of Chinese Academy of Agricultural Science, Lanzhou, 730050, People’s Republic of China; 2Department of Animal Health Technology, Oyo State College of Agriculture and Technology, Igboora, 201103, Nigeria; 3Department of Veterinary Science, Hamelmalo Agricultural College, Keren, 397, EritreaCorrespondence: Zuoting YanKey Laboratory of Veterinary Pharmaceutical Development of Ministry of Agriculture, Lanzhou Institute of Husbandry and Pharmaceutical Sciences of Chinese Academy of Agricultural Science, Lanzhou, 730050, People’s Republic of China, Tel +8613919067215, Email yanzuoting@caas.cnPurpose: Endometritis is a female reproductive disease that affects the cattle industries development and microRNAs (miRNAs) play a pivotal role and critical regulators of the innate immune response in varieties of diseases. The present study intends to investigate the regulatory role of miR‐24-3p in the innate immune response involved in endometritis and evaluate its therapeutic potential.Methods: Whole mice uteri and bovine endometrial epithelial cells (BEECs) were separately stimulated with LPS. The BEECs were also transfected with miR-24-3p mimic and negative control; siTRAF6 and siNC; pcDNA3.1 empty and pcDNA3.1(+)TRAF6 separately with LPS stimulation. The expression levels of miR‐24-3p and TRAF6 were measured via quantitative real‐time polymerase chain reaction (qRT-PCR) and Western blot, respectively. LPS‐induced inflammatory response assessed by inflammatory cytokines secretion and expression via ELISA and qRT-PCR. Bioinformatics analysis and luciferase reporter assay validated the interaction between miR‐24-3p and TRAF6. The activation of the NF

Gang Shen,1,* Yinping Du,1,* Jifang Shen,1 Junling Zhang,2 Xihua Xia,2 Mengli Huang,2 Wenxiang Shen3 1Department of Radiology, The Affiliated Kunshan Hospital of Jiangsu University, Kunshan, People’s Republic of China; 2The Medical Department, 3D Medicines, Inc., Shanghai, People’s Republic of China; 3Department of Oncology, The Affiliated Kunshan Hospital of Jiangsu University, Kunshan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Wenxiang ShenDepartment of Oncology, The Affiliated Kunshan Hospital of Jiangsu University, 91 West Qianjin Road, Kunshan, Jiangsu Province, 215300, People’s Republic of ChinaEmail shenwenxiang329@163.comAbstract: Lung cancer is still the leading cause of morbidity and mortality by cancer among men, according to the latest epidemiological data in China. Anaplastic lymphoma kinase (ALK) rearrangements act as key oncogenic drivers of non-small cell lung cancer (NSCLC) and have been identified in 5– 6% of NSCLC. Although ALK inhibitors (ALK-TKIs) were proven to be more effective than chemotherapy in ALK-positive NSCLC patients and the safety profile of these drugs was favorable, novel ALK fusions NSCLC might discontinue or switch treatment because of adverse events (AEs) have rarely previously been reported. Here, we describe a male patient with stage IV lung adenocarcinoma who carried a novel PTH2R-ALK fusion identified by next-generation sequencing (NGS). The patient first took crizotinib but switched to alectinib due to gastrointestinal AEs. Although alectinib remained effective on tumors, ceritinib (450 mg) was replaced after the AEs of hyperbilirubinemia occurred. After reducing the dose to 300mg, the diarrhea AEs caused by ceritinib were effectively relieved, and the patient obtained sustained clinical benefit with progression-free survival nearly 12 months. Our findings offer valuable information for the safety management of NSCLC patients with a novel PTH2R

Bo Shen,1,* Hua Jiang,2,* Lin Wang,3,* Jun Qian,4,* Yongqian Shu,5 Ping Chen,6 Guoxin Mao,7 Baorui Liu,8 Xizhi Zhang,9 Chaoying Liu,10 Jun Wu,11 Xiaoqin Li,12 Wei Cai,13 Wenxiang Shen,14 Qiong Wang,15 Jingdong He,16 Dong Hua,17 Ziwen Zhang,18 Youcheng Zhang,19 Jifeng Feng1 1Department of Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, People’s Republic of China; 2Department of Oncology, Changzhou No. 2 People’s Hospital, Changzhou, People’s Republic of China; 3Department of Oncology, Bayi Hospital of People’s Liberation Army, Nanjing, People’s Republic of China; 4Department of Oncology, Suzhou Municipal Hospital, Suzhou, People’s Republic of China; 5Department of Oncology, Jiangsu Province Hospital, Nanjing, People’s Republic of China; 6Department of Oncology, Yancheng City No. 1 People’s Hospital, Yancheng, People’s Republic of China; 7Department of Oncology, Affiliated Hospital of Nantong University, Nantong, People’s Republic of China; 8Department of Oncology, Nanjing Drum Tower Hospital, Nanjing, People’s Republic of China; 9Department of Oncology, Northern Jiangsu People’s Hospital, Yangzhou, People’s Republic of China; 10Department of Oncology, Wuxi People’s Hospital, Wuxi, People’s Republic of China; 11Department of Oncology, The First People’s Hospital of Changzhou, Changzhou, People’s Republic of China; 12Department of Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, People’s Republic of China; 13Department of Oncology, The First People’s Hospital of Wujiang, Wujiang, People’s Republic of China; 14Department of Oncology, The First People’s Hospital of Kunshan, Kunshan, People’s Republic of China; 15Department of Oncology, Jian